Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales

Lung Cancer

Volumn 88, Issue 3, 2015, Pages 344-348

  Beckett, P ^a,b   Edwards, J ^c   Fennell, D ^d   Hubbard, R ^e   Woolhouse, I ^b,f   Peake, M D ^b,g  

^a ROYAL DERBY HOSPITAL   (United Kingdom)

^b ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^f QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^g GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

Audit; Chemotherapy; Mesothelioma; Performance status; Stage; Surgery; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CYTOLOGY; DEMOGRAPHY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURODESIS; PRIORITY JOURNAL; SECONDARY HEALTH CARE; UNITED KINGDOM; VERY ELDERLY; YOUNG ADULT; CANCER GRADING; CANCER STAGING; ENGLAND; HEALTH SURVEY; LUNG NEOPLASMS; MESOTHELIOMA; MORTALITY; PLEURAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALES;

ADULT; AGED; AGED, 80 AND OVER; ENGLAND; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PLEURAL NEOPLASMS; POPULATION SURVEILLANCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WALES; YOUNG ADULT;

EID: 84929519753     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.03.005     Document Type: Article

References (17)

1. Tan E., Warren N., Darnton A.J., et al. Projection of mesothelioma mortality in Britain using Bayesian methods. Br J Cancer 2010, 103:430-436. 10.1038/sj.bjc.6605781.
2. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21:2636-2644. 10.1200/JCO.2003.11.136.
3. Datta A., Smith R., Fiorentino F., et al. Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position. Thorax 2014, 69:194-197. 10.1136/thoraxjnl-2013-203846.
4. Price A. What is the role of radiotherapy in malignant pleural mesothelioma?. Oncologist 2011, 16:359-365. 10.1634/theoncologist.2010-0185.
5. Yates D.H., Corrin B., Stidolph P.N., et al. Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 1997, 52:507-512. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1758573&tool=pmcentrez&rendertype=abstract [accessed 06.04.14].
6. British Thoracic Society Standards of Care Committee BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007, 62(Suppl. 2). ii1-19. 10.1136/thx.2007.087619.
7. Department of Health Mesothelioma framework: advice for the NHS on how to organise services for malignant pleural mesothelioma (MPM) patients to improve quality of care across the country 2007, 1-53. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_072348.
8. Treasure T., Lang-Lazdunski L., Waller D., et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomised feasibility study. Lancet Oncol 2011, 10.1016/S1470-2045(11)70149-8.
9. Rintoul R.C., Ritchie A.J., Edwards J.G., et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 2014, 10.1016/S0140-6736(14)60418-9.
10. Beckett P., Woolhouse I., Stanley R., et al. Exploring variations in lung cancer care across the UK - the "story so far" for the National Lung Cancer Audit. Clin Med 2012, 12:14-18. http://www.ncbi.nlm.nih.gov/pubmed/22372213 [accessed 08.10.13].
11. Office for National Statistics Cancer Statistics Registrations. Cancer Stat. Regist. 2011, http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-302299 [accessed 22.02.14].
12. Rich A.L., Tata L.J., Free C.M., et al. Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service. Thorax 2011, 66:1078-1084. 10.1136/thx.2011.158972.
13. Beckett P., Callister M., Tata L.J., et al. Clinical management of older people with non-small cell lung cancer in England. Thorax 2012, 67:836-839. 10.1136/thoraxjnl-2011-200994.
14. Health and Social Care Information Centre: 2012 Patient Cohort Lung Cancer Audit Report 2013, 1-56. http://www.hscic.gov.uk/catalogue/PUB12719/clin-audi-supp-prog-lung-nlca-2013-rep.pdf.
15. Rice D., Rusch V., Pass H., et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest. J Thorac Oncol 2011, 6:1304-1312. 10.1097/JTO.0b013e3182208e3f.
16. Health and Social Care Information Centre National Lung Cancer Audit Report: 2013 Patient Cohort 2014, http://www.hscic.gov.uk/catalogue/PUB16019/clin-audi-supp-prog-lung-nlca-2014-rep.pdf.
17. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995, 108:1122-1128. http://wwwncbinlmnihgov/pubmed/7555126 [accessed 17.04.14].